+

WO2007036920A3 - Utilisation d'acide polyanhydroglucronique - Google Patents

Utilisation d'acide polyanhydroglucronique Download PDF

Info

Publication number
WO2007036920A3
WO2007036920A3 PCT/IE2006/000104 IE2006000104W WO2007036920A3 WO 2007036920 A3 WO2007036920 A3 WO 2007036920A3 IE 2006000104 W IE2006000104 W IE 2006000104W WO 2007036920 A3 WO2007036920 A3 WO 2007036920A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
paga
copolymer
salt
polyanhydroglucronic
Prior art date
Application number
PCT/IE2006/000104
Other languages
English (en)
Other versions
WO2007036920A2 (fr
Inventor
Jiri Briestensky
Ivan Santar
Vladimir Semecky
Petr Nachtigal
Anthony Richardson
Keith Real
Original Assignee
Alltracel Dev Services Ltd
Jiri Briestensky
Ivan Santar
Vladimir Semecky
Petr Nachtigal
Anthony Richardson
Keith Real
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltracel Dev Services Ltd, Jiri Briestensky, Ivan Santar, Vladimir Semecky, Petr Nachtigal, Anthony Richardson, Keith Real filed Critical Alltracel Dev Services Ltd
Publication of WO2007036920A2 publication Critical patent/WO2007036920A2/fr
Publication of WO2007036920A3 publication Critical patent/WO2007036920A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition comprenant un premier composant sélectionné parmi un acide polyanhydroglucuronique anionique biocompatible (PAGA), un sel de celui-ci, un copolymère de celui-ci et un complexe intermoléculaire de celui-ci et un second composant comprenant un agent anti-lipémique. L'invention concerne également l'utilisation d'un acide polyanhydroglucuronique anionique biocompatible (PAGA), d'un sel de celui-ci, d'un copolymère de celui-ci ou d'un complexe intermoléculaire de celui-ci dans la préparation d'un médicament destiné au traitement d'inflammation et l'utilisation d'un acide polyanhydroglucuronique anionique biocompatible (PAGA), d'un sel de celui-ci, d'un copolymère de celui-ci ou d'un complexe intermoléculaire de celui-ci dans la préparation d'un médicament destiné à maintenir la concentration en glucose dans le sang à un niveau physiologique.
PCT/IE2006/000104 2005-09-28 2006-09-28 Utilisation d'acide polyanhydroglucronique WO2007036920A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72107305P 2005-09-28 2005-09-28
US60/721,073 2005-09-28

Publications (2)

Publication Number Publication Date
WO2007036920A2 WO2007036920A2 (fr) 2007-04-05
WO2007036920A3 true WO2007036920A3 (fr) 2008-03-06

Family

ID=37561165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE2006/000104 WO2007036920A2 (fr) 2005-09-28 2006-09-28 Utilisation d'acide polyanhydroglucronique

Country Status (2)

Country Link
IE (1) IE20060710A1 (fr)
WO (1) WO2007036920A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20120268A1 (it) * 2012-12-03 2014-06-04 Diopeite Consulting Ltd Composizioni farmaceutiche per il trattamento dell'obesita'

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006405A1 (fr) * 1996-08-09 1998-02-19 Raisio Benecol Ltd. Composition de stanol et son utilisation
WO2000004907A1 (fr) * 1998-07-21 2000-02-03 Alpenstock Holdings Limited Formulation antilipemique
US20020110531A1 (en) * 2001-02-14 2002-08-15 Steven Faust Cholesterol reducing composition and method of making the same
WO2003068245A1 (fr) * 2002-02-14 2003-08-21 Alpenstock Holdings Limited Utilisation d'acide polyanhydroglucuronique renfermant de la cellulose oxydee microdispersee en tant qu'immunomodulateur

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006405A1 (fr) * 1996-08-09 1998-02-19 Raisio Benecol Ltd. Composition de stanol et son utilisation
WO2000004907A1 (fr) * 1998-07-21 2000-02-03 Alpenstock Holdings Limited Formulation antilipemique
US20020110531A1 (en) * 2001-02-14 2002-08-15 Steven Faust Cholesterol reducing composition and method of making the same
WO2003068245A1 (fr) * 2002-02-14 2003-08-21 Alpenstock Holdings Limited Utilisation d'acide polyanhydroglucuronique renfermant de la cellulose oxydee microdispersee en tant qu'immunomodulateur

Also Published As

Publication number Publication date
WO2007036920A2 (fr) 2007-04-05
IE20060710A1 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
CA2764331C (fr) Composition de traitement cutane anti-infectieux
WO2007149310A3 (fr) Nano-composants multiphasiques biofonctionnels et procédés d'utilisation desdits nano-composants
WO2006041942A3 (fr) Apport oculaire de preparations d'apport polymere
WO2007002572A3 (fr) Nattokinase pour reduire la viscosite du sang total
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
EP1586338A3 (fr) Utilisation d'antioxydants pour la prévention d'oxydation et la réduction de la dégradation des principes actifs dans les articles médicaux libérant des principes actifs
WO2009076547A8 (fr) Dispositif implantable d'administration de médicaments et procédés pour le traitement de la vessie et d'autres vésicules ou lumières du corps
TR200201440T2 (tr) Biomedikal kullanım için radyum-223 hazırlanması
WO2006082588A3 (fr) Procede et dispositif d'administration ophtalmique d'ingredients pharmaceutiquement actifs
WO2004003164A3 (fr) Methodes destinees a la regeneration d'organes
EP2108390A3 (fr) Dispositif pour administration locale et/ou régionale utilisant des agents thérapeutiques sous forme liquide
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
DE602004030931D1 (fr)
WO2007025142A3 (fr) Compositions et procedes pour le traitement de surface dans des procedures medicales et chirurgicales
EP1637132A4 (fr) Preparation externe permettant de traiter les pieds d'un athlete
WO2002060410A3 (fr) Methodes d'administration locale a liberation prolongee de medicaments visant a l'ablation de tissus non desires
WO2006078277A3 (fr) Compositions de dalbavancin pour le traitement d'infections bacteriennes
EP1643999B8 (fr) Utilisation de pyridoxamine pour traiter nephropathie dans type ii diabete
EP1226822A3 (fr) Promoteurs de la production de l'oxyde d'azote et de la NO synthéthase, compositions cosmétiques et pharmaceutiques les contenant
MXPA05008461A (es) Equipo para aplicar revestimiento de farmaco a un dispositivo medico en un cuarto del cirujano.
WO2008088536A8 (fr) Libération différentielle de médicament à partir d'un dispositif médical
WO2007036920A3 (fr) Utilisation d'acide polyanhydroglucronique
TR200103665T2 (tr) Nöro ve -retino-koruyucu oftalmolojik ilaçlar
WO2003001877A3 (fr) Diagnostic et traitement des rejets de tissu cardiaque
ES2182840T3 (es) Factor xiii para el tratamiento de heridas de la piel.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06796046

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载